Juno Therapeutics, A Subsidiary Of Celgene
Clinical trials sponsored by Juno Therapeutics, A Subsidiary Of Celgene, explained in plain language.
-
New CAR-T cell therapy trial offers hope for patients with Tough-to-Treat blood cancers
Disease control Recruiting nowThis study is testing an experimental cell therapy called JCAR017 for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to figh…
Phase: PHASE1, PHASE2 • Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Last-Chance cell therapy offered when standard drug fails quality checks
Disease control AVAILABLEThis program provides access to a non-standard version of a personalized cell therapy (lisocabtagene maraleucel) for adults with a type of aggressive lymphoma. It is for patients who were already prescribed this therapy, but the specific batch made for them did not pass all stand…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC